Long-term study to inform gene therapy development
Genespire has commenced patient enrolment in an observational study, InforMMA, in children with methylmalonic acidemia (MMA) caused by mutations in the MMUT gene.
The study is designed to follow patients aged up to 16 years who live with severe MMA, with the aim of better characterising disease progression over time.
It will enrol patients both with and without prior liver or kidney transplantation; however, both groups must be assessed as having the “severe” MMA phenotype.
The research will support the ongoing development of GENE202, the company’s immune-shielded lentiviral vector gene therapy designed specifically for MMA.
By conducting longitudinal measurements of specific biochemical markers and clinical outcomes linked to metabolic stability and disease trajectory over a 36-month period from baseline, Genespire hopes to deepen the understanding of MMUT-associated MMA.
The study will enrol patients at a total of seven sites in the US and Europe, all of which are renowned metabolic or paediatric centres of excellence.
“Observational studies like this require time, resources and close collaboration with the wider community – but they are fundamental to innovation in rare disease,” said Lucia Faccio, CEO of Genespire. “By investing early in our understanding of MMA, we aim to optimise the later stages of development for GENE202.”
“For far too long, patients with MMA have been underserved by healthcare systems and underrepresented in research, leaving substantial gaps in our understanding of disease progression over time,” added Dr Maddalena Migliavacca, principal investigator at InforMMA’s Ospedale San Raffaele site. “This study represents an important step towards developing a more comprehensive understanding of the real-world patient experience and, ultimately, improving outcomes for patients and their families.”
